These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 33624409)

  • 1. Durvalumab-induced lesions of bronchiolitis and fully reversible bronchiectasis in a patient with non-small cell lung cancer: A case report.
    Domblides M; Geier M; Decroisette C; Descourt R
    Thorac Cancer; 2021 Apr; 12(8):1240-1243. PubMed ID: 33624409
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Durvalumab for the treatment of non-small cell lung cancer.
    Murakami S
    Expert Rev Anticancer Ther; 2019 Dec; 19(12):1009-1016. PubMed ID: 31782989
    [No Abstract]   [Full Text] [Related]  

  • 3. Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study.
    Garassino MC; Cho BC; Kim JH; Mazières J; Vansteenkiste J; Lena H; Corral Jaime J; Gray JE; Powderly J; Chouaid C; Bidoli P; Wheatley-Price P; Park K; Soo RA; Huang Y; Wadsworth C; Dennis PA; Rizvi NA;
    Lancet Oncol; 2018 Apr; 19(4):521-536. PubMed ID: 29545095
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Durvalumab in non-small-cell lung cancer patients: current developments.
    Mezquita L; Planchard D
    Future Oncol; 2018 Feb; 14(3):205-222. PubMed ID: 29140105
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety evaluation of durvalumab for the treatment of non-small-cell lung cancer.
    Shibata Y; Murakami S
    Expert Opin Drug Saf; 2020 Jun; 19(6):653-659. PubMed ID: 32357806
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term response with durvalumab after chemoradiotherapy for pulmonary pleomorphic carcinoma: A case report.
    Yorozuya T; Taya T; Yasuda K; Nagano Y; Shioya M; Chiba H; Takahashi H
    Thorac Cancer; 2020 Apr; 11(4):1090-1093. PubMed ID: 32045109
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of psoriatic arthritis during nivolumab therapy for metastatic non-small cell lung cancer, clinical outcome analysis and review of the literature.
    Ruiz-Bañobre J; Pérez-Pampín E; García-González J; Gómez-Caamaño A; Barón-Duarte FJ; López-López R; Vázquez-Rivera F
    Lung Cancer; 2017 Jun; 108():217-221. PubMed ID: 28625638
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical Activity, Tolerability, and Long-Term Follow-Up of Durvalumab in Patients With Advanced NSCLC.
    Antonia SJ; Balmanoukian A; Brahmer J; Ou SI; Hellmann MD; Kim SW; Ahn MJ; Kim DW; Gutierrez M; Liu SV; Schöffski P; Jäger D; Jamal R; Jerusalem G; Lutzky J; Nemunaitis J; Calabrò L; Weiss J; Gadgeel S; Bhosle J; Ascierto PA; Rebelatto MC; Narwal R; Liang M; Xiao F; Antal J; Abdullah S; Angra N; Gupta AK; Khleif SN; Segal NH
    J Thorac Oncol; 2019 Oct; 14(10):1794-1806. PubMed ID: 31228626
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Successful treatment of a patient with non-small cell lung cancer and interstitial lung disease with durvalumab: a case report.
    Tao H; Li F; Li R; Han X; Hu Y
    Ann Palliat Med; 2020 Sep; 9(5):3623-3628. PubMed ID: 32648466
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Retreatment with anti-PD-1 antibody in non-small cell lung cancer patients previously treated with anti-PD-L1 antibody.
    Fujita K; Yamamoto Y; Kanai O; Okamura M; Hashimoto M; Nakatani K; Sawai S; Mio T
    Thorac Cancer; 2020 Jan; 11(1):15-18. PubMed ID: 31701630
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune checkpoint-inhibitors and chemoradiation in stage III unresectable non-small cell lung cancer.
    Melosky B; Juergens R; McLeod D; Leighl N; Brade A; Card PB; Chu Q
    Lung Cancer; 2019 Aug; 134():259-267. PubMed ID: 31319991
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Durvalumab for the treatment of non-small cell lung cancer.
    Mezquita L; Planchard D
    Expert Rev Respir Med; 2018 Aug; 12(8):627-639. PubMed ID: 29958099
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Myositis induced by durvalumab in a patient with non-small cell lung cancer: A case report.
    Kobayashi M; Saiki M; Omori C; Ide S; Masuda K; Sogami Y; Hata T; Ishihara H
    Thorac Cancer; 2020 Dec; 11(12):3614-3617. PubMed ID: 33103845
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study.
    Antonia S; Goldberg SB; Balmanoukian A; Chaft JE; Sanborn RE; Gupta A; Narwal R; Steele K; Gu Y; Karakunnel JJ; Rizvi NA
    Lancet Oncol; 2016 Mar; 17(3):299-308. PubMed ID: 26858122
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [IoNESCO trial: Immune neoajuvant therapy in early stage non-small cell lung cancer].
    Mignard X; Antoine M; Moro-Sibilot D; Dayen C; Mennecier B; Gervais R; Amour E; Milleron B; Morin F; Zalcman G; Wislez M
    Rev Mal Respir; 2018 Nov; 35(9):983-988. PubMed ID: 30243521
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Durvalumab for stage III non-small-cell lung cancer patients: clinical evidence and real-world experience.
    Botticella A; Mezquita L; Le Pechoux C; Planchard D
    Ther Adv Respir Dis; 2019; 13():1753466619885530. PubMed ID: 31686616
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Peripheral Blood Markers Identify Risk of Immune-Related Toxicity in Advanced Non-Small Cell Lung Cancer Treated with Immune-Checkpoint Inhibitors.
    Pavan A; Calvetti L; Dal Maso A; Attili I; Del Bianco P; Pasello G; Guarneri V; Aprile G; Conte P; Bonanno L
    Oncologist; 2019 Aug; 24(8):1128-1136. PubMed ID: 31015312
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antibiotics are associated with attenuated efficacy of anti-PD-1/PD-L1 therapies in Chinese patients with advanced non-small cell lung cancer.
    Zhao S; Gao G; Li W; Li X; Zhao C; Jiang T; Jia Y; He Y; Li A; Su C; Ren S; Chen X; Zhou C
    Lung Cancer; 2019 Apr; 130():10-17. PubMed ID: 30885328
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association Between Immune-related Adverse Events and Efficacy of Immune Checkpoint Inhibitors in Non-small-cell Lung Cancer.
    Grangeon M; Tomasini P; Chaleat S; Jeanson A; Souquet-Bressand M; Khobta N; Bermudez J; Trigui Y; Greillier L; Blanchon M; Boucekine M; Mascaux C; Barlesi F
    Clin Lung Cancer; 2019 May; 20(3):201-207. PubMed ID: 30442524
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectivity and safety of PD-1/PD-L1 inhibitors for different level of PD-L1-positive, advanced NSCLC: A meta-analysis of 4939 patients from randomized controlled trials.
    Shi Y; Duan J; Guan Q; Xue P; Zheng Y
    Int Immunopharmacol; 2020 Jul; 84():106452. PubMed ID: 32339922
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.